Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Navidea Biopharmaceuticals Inc NAVB

Healthcare Biotechnology
Navidea Biopharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It is developing multiple precision-targeted products based on its Manocept platform to enhance patient care by identifying the sites and pathways of undetected disease. The Company’s business is focused on... see more

Recent & Breaking News (GREY:NAVB)

Navidea Biopharmaceuticals to Announce Fourth Quarter and Year-End 2014 Financial Results on March 5, 2015

Business Wire February 26, 2015

Lymphoseek® Data Presented in European Medical Conference Reinforces Clinical Value in Head & Neck Cancer of the Oral Cavity

Business Wire February 18, 2015

Lymphoseek® Results from Phase 3 Clinical Trial in Oral Cavity Cancer of the Head and Neck Published in Annals of Surgical Oncology

Business Wire February 17, 2015

Navidea Reports Preliminary 2014 Revenue; Provides Update on New Commercial Strategy

Business Wire February 9, 2015

Navidea to Report Preliminary 2014 Revenue and Present at BIO CEO & Investor Conference February 9

Business Wire February 2, 2015

Lymphoseek® Performance vs. Sulfur Colloid in Breast Cancer Patients Published in Annals of Surgical Oncology; Fewer Nodal Dissections Required

Business Wire January 29, 2015

Navidea's Macrophage Therapeutics Unit Announces Plan for $2.5 Million Financing

Business Wire January 21, 2015

Navidea Biopharmaceuticals to Present at Biotech Showcase 2015

Business Wire January 6, 2015

Navidea Strengthens Leadership Team to Accelerate Lymphoseek® Growth

Business Wire January 5, 2015

Data Presented by Independent Academic Collaborators Demonstrate Ability of Novel Manocept(TM) Immunotherapy to Kill Activated Macrophages from KS Patients

Business Wire December 15, 2014

Macrophage Therapeutics to Present Data Supporting Potential for Breakthrough with Manocept(TM) in Immunotherapy

Business Wire December 12, 2014

Navidea Forms Macrophage Therapeutics Business Unit to Explore Therapeutic Applications of Manocept(TM)

Business Wire December 10, 2014

Navidea Biopharmaceuticals to Present at the 2014 LD Micro Conference

Business Wire November 25, 2014

European Commission Approves Navidea's Sentinel Lymph Node Detection Agent Lymphoseek®

Business Wire November 20, 2014

Navidea Receives $1.1Million PDUFA Filing Fee Refund for Award of Orphan Drug Status; Platinum Partners Reaffirms Commitment to Line of Credit

Business Wire November 11, 2014

Navidea Announces Third Quarter 2014 Financial Results

Business Wire November 6, 2014

Navidea Announces Scientific Presentations of Results from Lymphoseek® Studies at the European Association of Nuclear Medicine and European Society of Surgical Oncology Meetings

Business Wire October 30, 2014

Navidea Biopharmaceuticals to Announce Third Quarter 2014 Financial Results on November 6, 2014

Business Wire October 29, 2014

Navidea Announces Rick Gonzalez as New Chief Executive Officer

Business Wire October 15, 2014

FDA Approves Expanded Use of Navidea's Lymphoseek® for Lymphatic Mapping in Solid Tumors

Business Wire October 15, 2014